Clinical Trials Logo
  1. Home
  2. Norovirus Infections
  3. NCT04875676

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines — VXA-NVV-105  

Norovirus Infections Clinical Trial

Official title:
A Phase 1b, Open-label, Boost-optimization Study of an Adenoviral- Vector Based Oral Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 Administered Orally to Healthy Adult Volunteers

Clinical Trial Summary

To evaluate the immunogenicity of VXA-G1.1-NN with repeat-dose administration at Day 1 and varying boost schedules (Week 4, 8 or 12 post initial dose) in healthy adults aged 18-55, inclusive, and to assess the safety and tolerability of VXA- G1.1-NN with repeat-dose administration at varying boost schedules (Week 4, 8 or 12) in healthy adults aged 18-55, inclusive

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04875676
Study type Interventional
Source Vaxart
Contact
Status Completed
Phase Phase 1/Phase 2
Start date April 30, 2021
Completion date October 30, 2021
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02371538 - Human Breastmilk in Young Children With Norovirus Infection of the Gut N/A
Completed NCT04188691 - A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine Phase 1
Recruiting NCT04941261 - Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha) Phase 2
Not yet recruiting NCT05916326 - Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha) Phase 3
Completed NCT05212168 - Norovirus Challenge Study Phase 1/Phase 2
Completed NCT05213728 - A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers Phase 1
Completed NCT06211621 - Admission Pattern Among Children With Gastro-intestinal Infections Before and During the Covid-19 Pandemic
Active, not recruiting NCT05626803 - A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers Phase 2
Completed NCT01435811 - Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1) Phase 1
Completed NCT04854746 - Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine Phase 1